Navigation Links
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Date:10/27/2008

ients experienced SAEs and no tuberculosis or opportunistic infections were reported. Between weeks 24 and 52, one colon and one small cell lung cancer were reported. The small cell lung cancer patient died; another patient died in a climbing accident. Through one year, golimumab had a similar safety profile to the first 6 months.

Anti-TNF therapies have been associated with serious and sometimes fatal risks including the risk of tuberculosis and other serious infections, malignancies, heart failure, central nervous system disorders, reactivation of hepatitis B and other serious events.

About Psoriatic Arthritis

Psoriatic arthritis is a chronic inflammatory arthropathy manifesting with joint pain and swelling that can lead to joint destruction and debilitation. It is frequently associated with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness and tenderness of the joints and surrounding tissue and reduced range of motion. Joints of the hands, wrists, knees, ankles, feet, lower back and neck are commonly affected. Psoriasis affects an estimated two to three percent of the world's population, and approximately one out of three patients affected by psoriasis may develop psoriatic arthritis. Both men and women are equally affected by psoriatic arthritis, most commonly between the ages 30 and 50, in the peak of their productive years.

About Golimumab

Golimumab, the next-generation human anti-TNF-alpha monoclonal antibody from Centocor Inc. and Schering-Plough Corporation, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF-alpha biologic therapy. With ongoing studies for the treatment of rheumatoid arthritis (RA), psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as an every four-week subcutaneous injection and an intravenous (IV) infusion therapy. Golimumab targets and neutralizes both the soluble and membrane-bou
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care
5. Finesse Solutions Launches Improved E-Store for Sensors and Transmitters
6. Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
7. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
8. Improved culture system for hepatitis C virus infection
9. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: ... promotions as well as changes to Martine Rothblatt ... Promotions United Therapeutics announced the promotion ... Co-Chief Executive Officer and David Zaccardelli , Pharm.D. ... connection with these promotions, Dr. Rothblatt,s title will change ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
(Date:12/15/2014)... , Dec. 15, 2014  Origin Agritech Limited (NASDAQ GS: ... technology-focused supplier of crop seeds in China ... its fiscal year 2014 ended September 30, 2014, before the ... Company will host a teleconference on January 8, 2015, at ... time to discuss the results. To participate in the ...
(Date:12/13/2014)... December 12, 2014 Clarassance, a privately ... its new name: Therabron Therapeutics , Inc. The ... bronchioles (a type of structure in the lungs similar ... mission to develop novel protein therapeutics for the treatment ... decided to change the name to mark the company's ...
Breaking Biology Technology:United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... The Center for Molecular Biology,(CMB) has received an ... Gates,Foundation to support continued development of an avian ... develop vaccines against,highly pathogenic avian influenza viruses of ... clinical trials. , Dr. ...
... ArunA Biomedical, Inc., announced today that it will make ... in early 2009. The cells, derived from NIH ... normal, consistent population of neural cells in an adherent ... research community. hN2 cells provide a human cell ...
... EUCODIS Bioscience, a company,developing enzymes for the chemical industry, ... Chief Financial Officer. , "We ... brings to,EUCODIS Bioscience," said Rudy Pandjaitan, Ph.D., CEO of ... and his close relations,with the investment community will be ...
Cached Biology Technology:Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development 2ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells 2EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer 2
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 /PRNewswire-USNewswire/ ... efforts to make it easier to detect and ... chain. Today the agency started performing ... The capability will validate the authenticity of purchased ... chain. The new quality control measures will be ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... While hunting among chimpanzees is a group effort, key ... group. They are more likely to initiate a hunt, and ... study. The findings, which appear in the current issue ... animals cooperate to hunt for food, and how individual variation ...
... Ind. - Purdue University and USDA-Agricultural Research Service scientists ... plants halts infection by a disease-causing fungus that can ... research team is the first to show that the ... grasses - from the devastating, fungal pathogen. The naturally ...
... from an innovative computational approach could speed up the ... development, researchers from the University of Chicago Medical Center ... published in the February 2008 issue of Genome Research, ... of the human genes and proteins that serve as ...
Cached Biology News:Key 'impact hunters' catalyze hunting among male chimpanzees 2Key 'impact hunters' catalyze hunting among male chimpanzees 3Gene guards grain-producing grasses so people and animals can eat 2Gene guards grain-producing grasses so people and animals can eat 3Study of successful drug targets could hasten development of new medications 2Study of successful drug targets could hasten development of new medications 3
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
... The Lambda 10-2 is a microprocessor ... impressive speed coupled with exceptionally smooth ... for research applications involving fluorescence microscopy, ... any application requiring rapid and accurate ...
... FL is equipped with ... measurement technologies that complement ... advanced features of Fluoroskan ... Fluoroskan Ascent FL provides ...
... an enzyme that catalyzes the hydrolysis ... maltotriose, and dextrins. The,level of a-amylase ... body is of,clinical significance in the ... diabetes; plant and microbial a-amylases are,important ...
Biology Products: